Drug and Therapy Development for Triple Negative Breast Cancer
1. Edition July 2023
320 Pages, Hardcover
Handbook/Reference Book
ISBN:
978-3-527-35175-6
Wiley-VCH, Weinheim
Short Description
A holistic view on TNBC that integrates the latest advances in the etiology, detection, diagnosis and treatment of this agressive cancer, laying the ground for the development of novel therapies.
Buy now
Price: 139,00 €
Price incl. VAT, excl. Shipping
Euro prices for Wiley-VCH and Ernst & Sohn titles are only valid for Germany. In EU countries, local VAT applies. Postage will be charged.
Further versions
HISTORY OF BREAST CANCER
Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches
DNA replication stress and genome instability in breast cancer
Recent advancement of nanotherapeutics to treat breast cancer
HER Receptor in Breast Cancer
Human endogenous retroviruses in triple negative breast cancer
NOVEL DRUG DISCOVERY AND DEVELOPMENT
Development in Drug repurposing for the treatment of acute leukemia complicating metastatic breast cancer
Novel pharmaceutical nanomaterials to advance the current breast cancer treatment - Current trends and future perspective
ADVANCED TECHNOLOGIES IN BREAST CANCER THERAPY
Artificial intelligence-driven decisions in breast cancer diagnosis
Establishing nanotechnology-based drug development for triple-negative breast cancer treatment
Etiology and therapy of hormone receptor positive breast cancer
Donor-acceptor based heterocyclic compounds as chemotherapy and photothermal agents in treatment of breast cancer cell
REGULATORY, CLINICAL ASPECTS AND CASE STUDIES
An insight into drug regulatory affairs and the procedures
A comprehensive review of some heat shock proteins in the development and progression of human breast cancer
Nanoparticle-based therapeutics for triple negative breast cancer
Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches
DNA replication stress and genome instability in breast cancer
Recent advancement of nanotherapeutics to treat breast cancer
HER Receptor in Breast Cancer
Human endogenous retroviruses in triple negative breast cancer
NOVEL DRUG DISCOVERY AND DEVELOPMENT
Development in Drug repurposing for the treatment of acute leukemia complicating metastatic breast cancer
Novel pharmaceutical nanomaterials to advance the current breast cancer treatment - Current trends and future perspective
ADVANCED TECHNOLOGIES IN BREAST CANCER THERAPY
Artificial intelligence-driven decisions in breast cancer diagnosis
Establishing nanotechnology-based drug development for triple-negative breast cancer treatment
Etiology and therapy of hormone receptor positive breast cancer
Donor-acceptor based heterocyclic compounds as chemotherapy and photothermal agents in treatment of breast cancer cell
REGULATORY, CLINICAL ASPECTS AND CASE STUDIES
An insight into drug regulatory affairs and the procedures
A comprehensive review of some heat shock proteins in the development and progression of human breast cancer
Nanoparticle-based therapeutics for triple negative breast cancer
Dr. Pravin Kendrekar, School of Natural Sciences, University of Central Lancashire, Preston, UK.
Dr. Vinayak Adimule, Angadi Institute of Technology and Management, Belagavi, India.
Dr. Tara Hurst, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Dr. Vinayak Adimule, Angadi Institute of Technology and Management, Belagavi, India.
Dr. Tara Hurst, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
